Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Reata Pharmaceuticals, Inc.
  6. News
  7. Summary
    RETA   US75615P1030

REATA PHARMACEUTICALS, INC.

(RETA)
  Report
Delayed Nasdaq  -  04:00 2022-08-11 pm EDT
20.96 USD   -2.78%
08/09Baird Lowers Reata Pharmaceuticals' Price Target to $27 From $37, Maintains Market Neutral Rating
MT
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's Ataxia
BU
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Decline Premarket Wednesday

05/19/2021 | 09:20am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
Stocks mentioned in the article
ChangeLast1st jan.
111, INC. -2.53% 2.31 Delayed Quote.-34.00%
NASDAQ COMPOSITE -0.58% 12779.91 Real-time Quote.-17.83%
REATA PHARMACEUTICALS, INC. -2.78% 20.96 Delayed Quote.-20.52%
SO-YOUNG INTERNATIONAL INC. 0.30% 0.9412 Delayed Quote.-70.50%
All news about REATA PHARMACEUTICALS, INC.
08/09Baird Lowers Reata Pharmaceuticals' Price Target to $27 From $37, Maintains Market Neut..
MT
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug..
BU
08/09Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug..
CI
08/09Goldman Sachs Adjusts Price Target on Reata Pharmaceuticals to $76 From $73, Reiterates..
MT
08/08Reata Shares Down 33%; Reports 2Q and Details of FDA Meeting
DJ
08/08Cantor Fitzgerald Lowers Price Target for Reata Pharmaceuticals to $47 From $68, Mainta..
MT
08/08SECTOR UPDATE : Health Care Stocks Getting Late Boost Back to Positive Ground
MT
08/08SECTOR UPDATE : Health Care
MT
08/08Top Midday Decliners
MT
08/08Wall Street Set to Open in Positive Territory as Strong Employment Data Allay Recession..
MT
More news
Analyst Recommendations on REATA PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 3,18 M - -
Net income 2022 -307 M - -
Net cash 2022 218 M - -
P/E ratio 2022 -2,49x
Yield 2022 -
Capitalization 765 M 765 M -
EV / Sales 2022 172x
EV / Sales 2023 23,0x
Nbr of Employees 348
Free-Float 82,9%
Chart REATA PHARMACEUTICALS, INC.
Duration : Period :
Reata Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REATA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 20,96 $
Average target price 50,67 $
Spread / Average Target 142%
EPS Revisions
Managers and Directors
J. Warren Huff Chairman & Chief Executive Officer
Manmeet Singh Soni President, Chief Operating & Financial Officer
W. Christian Wigley Chief Scientific Officer & Senior Vice President
Edmund Doherty Vice President-Medical Affairs
Samina Khan Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
REATA PHARMACEUTICALS, INC.-20.52%765
GILEAD SCIENCES, INC.-13.99%78 273
VERTEX PHARMACEUTICALS33.04%74 927
REGENERON PHARMACEUTICALS, INC.-1.21%66 700
WUXI APPTEC CO., LTD.-20.30%40 674
BIONTECH SE-38.48%38 540